Effect Of Carvedilol On The Plasma Content Of NPY In Patients With ACS

Objective The relation between the plasma Neuropeptide Y(NPY) level and the myocardial ischemia in patients with acute coronary syndrome(ACS) and the effect of carvedilol on the plasma concentration of NPY in these patients were studied.Methods 62 cases of ACS patients including 28 patients with Q-wave AMI, 14 patients with non- Q-wave AMI and 20 patients with UA were involved in this study. Eath group was randomly divided into 2 groups, carvedilol-treated group and non-carvedilol-treated group. The plasma NPY concentrations were determined by radioimmunoassay (RIA) before and after treatment. 20 normal person's plasma NPY were measured as the normal control. Datas were analyzed by SPSS 11.5 soft ware using the methods of one-way ANOVA and linear regression.Results NPY level significantly increased in patients with ACS compared with that in normal control (all p<0.01). The NPY levels of patients with AMI (24h) and UA are significantly higher than that of normal controls and that of post 2 weeks treatment (p<0.05). The NPY level of patients with AMI is elevated from the beginning of AMI and reached the peak level at 3d after AMI, then declined to normal in 7d. After treatment of carvedilol NPY level was significantly decreased.Conclusion When ACS occurs, the plasma level of NPY is elevated. This suggests NPY may participate the pathophysiological course of ACS. The plasma NPY level may be a marker for judge the myocardial ischemia status of ACS patients. Carvedilol may improve the imbalance between myocardial oxygen supply and need in patients with ACS and also markedly antagonize the vasoconstriction of NPY.